A new PD-1-specific nanobody enhances the antitumor activity of T-cells in synergy with dendritic cell vaccine.
Animals
Antibodies, Monoclonal
/ immunology
CD8-Positive T-Lymphocytes
/ drug effects
Cancer Vaccines
/ pharmacology
Carcinoma, Hepatocellular
/ drug therapy
Carcinoma, Squamous Cell
/ drug therapy
Dendritic Cells
/ transplantation
Hep G2 Cells
Heterografts
Humans
Immune Checkpoint Inhibitors
/ pharmacology
Liver Neoplasms
/ drug therapy
Mice
Programmed Cell Death 1 Receptor
/ antagonists & inhibitors
Single-Domain Antibodies
/ immunology
T-Lymphocytes
/ drug effects
T-Lymphocytes, Cytotoxic
/ drug effects
Tongue Neoplasms
/ drug therapy
Cytotoxic T lymphocytes
Dendritic cell/tumor fused cell vaccine
Nanobody
PD-1 blockade
Tumor immunotherapy
Journal
Cancer letters
ISSN: 1872-7980
Titre abrégé: Cancer Lett
Pays: Ireland
ID NLM: 7600053
Informations de publication
Date de publication:
01 12 2021
01 12 2021
Historique:
received:
10
07
2021
revised:
14
09
2021
accepted:
17
09
2021
pubmed:
26
9
2021
medline:
8
1
2022
entrez:
25
9
2021
Statut:
ppublish
Résumé
Despite the many successes and opportunities presented by PD-1 blockade in cancer therapies, anti-PD-1 monoclonal antibodies still face multiple challenges. Herein we report a strategy based on a nanobody (Nb) to circumvent these obstacles. A new PD-1-blocking Nb (PD-1 Nb20) in combination with tumor-specific dendritic cell (DC)/tumor-fusion cell (FC) vaccine that aims to improve the activation, proliferation, cytokine secretion, and tumor cell cytotoxicity of CD8
Identifiants
pubmed: 34562519
pii: S0304-3835(21)00488-2
doi: 10.1016/j.canlet.2021.09.028
pii:
doi:
Substances chimiques
Antibodies, Monoclonal
0
Cancer Vaccines
0
Immune Checkpoint Inhibitors
0
PDCD1 protein, human
0
Programmed Cell Death 1 Receptor
0
Single-Domain Antibodies
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
184-197Informations de copyright
Copyright © 2021 Elsevier B.V. All rights reserved.